Company intelligence / Profile preview
Coherus BioSciences, Inc.
Redwood City, California, United Statescoherus.com ↗
- Ownership
- Public · CHRS
- Employees
- ~228
- Development stage
- Other
01
Overview
The company has successfully commercialized LOQTORZI, the first FDA-approved therapy for recurrent or metastatic nasopharyngeal carcinoma. It has a diversified pipeline of next-generation immuno-oncology candidates targeting the tumor microenvironment with ongoing clinical trials showing promising early data such as from CHS114 in head and neck cancer. Recently divested its UDENYCA biosimilar franchise to focus fully on innovative oncology therapies.
- Therapeutic areas
- Oncology
- Modalities
- Immunotherapies (including monoclonal antibodies)Biosimilars (previously marketed biosimilar products)Novel immuno-oncology agents targeting tumor microenvironment
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Financials
- Market cap
- $115.7M
- Total revenue
- $42.2M
- Enterprise value
- $48.1M
Beyond the preview
Go deeper on Coherus BioSciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coherus BioSciences, Inc..